<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00316303</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH072556</org_study_id>
    <secondary_id>R01MH072556</secondary_id>
    <secondary_id>DAHBR 9A-ASNM</secondary_id>
    <nct_id>NCT00316303</nct_id>
  </id_info>
  <brief_title>Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder</brief_title>
  <official_title>The STIRR Intervention for Dually Diagnosed Clients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <brief_summary>
    <textblock>
      This study will determine the effectiveness of the STIRR (Screen, Test, Immunize, Reduce
      risk, and Refer) intervention in increasing rates of testing, immunization, referral, and
      treatment for blood-borne diseases, such as hepatitis and HIV, in people with both a mental
      disorder and a substance abuse disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      People who have been dually diagnosed with a severe mental illness and a substance abuse
      disorder are at an elevated risk for contracting blood-borne infections, such as HIV,
      hepatitis B, and hepatitis C virus (HCV). Prevention, early detection, and treatment for
      these diseases are essential for this particular population. Research has shown that rates of
      HCV infection are 11 times higher in people with mental illnesses than in the general
      population. People with mental health illnesses and those with dual diagnoses should receive
      basic CDC-recommended services for risk screening and testing of HIV infection, AIDS, and
      hepatitis. They should also receive hepatitis A and B immunizations, risk reduction
      counseling, and referrals for medical care. However, most people with severe mental illnesses
      and substance abuse disorders do not receive the care they need. The STIRR (screen, test,
      immunize, reduce risk, and refer) intervention will provide necessary prevention and
      treatment services to an at-risk, under-treated population. This study will determine the
      effectiveness of the STIRR intervention in increasing rates of testing, immunization,
      referral, and treatment for blood-borne diseases, such as hepatitis and HIV, in people with
      both a mental disorder and a substance abuse disorder.

      Participants in this open-label study will be recruited from two publicly funded community
      mental health agencies in Baltimore, MD. Participants will be randomly assigned to receive
      either enhanced treatment as usual or the STIRR intervention. Individuals assigned to STIRR
      will attend three sessions over the course of 6 months. The first session will involve
      education, personalized risk assessment, risk reduction counseling, pre-test counseling,
      blood testing, and an initial immunization with Twinrix for hepatitis A and B viruses (HAV
      and HBV). At the second session, participants will receive their test results, as well as
      post-test and risk reduction counseling, medical referral and linkage, if necessary, and a
      second Twinrix immunization. The third session will include an assessment of risk level and
      reinforcement of risk reduction, a final immunization, an assessment of progress on treatment
      and linkage, and behavior reinforcement or modification. Enhanced treatment as usual will
      entail comprehensive mental health services provided at each study site, education about
      blood-borne diseases, and referral to a local community health provider for blood testing,
      HAV and HBV immunizations, and any necessary treatments. All participants will be assessed
      for treatment outcomes at Month 6. A 12-month post-intervention follow-up will be carried out
      with the infected participants in the STIRR group to evaluate quality of care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Immunization Status</measure>
    <time_frame>Measured at 6 Months relative to Baseline</time_frame>
    <description>Of the participants that were not immunized at baseline, the number of participants who were immunized for Hepatitis A and B at 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tested for Hepatitis C</measure>
    <time_frame>6 Months</time_frame>
    <description>Participant self-report of being tested for hepatitis C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tested for Hepatitis B</measure>
    <time_frame>6 Months</time_frame>
    <description>Participant self-report of being tested for hepatitis B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tested for HIV</measure>
    <time_frame>6 Months</time_frame>
    <description>Participant self-report of being tested for HIV</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Referral for Medical Care</measure>
    <time_frame>6 Months</time_frame>
    <description>For participants infected with hepatitis C, their self-report of being referred for medical care.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">236</enrollment>
  <condition>HIV Infections</condition>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Depression</condition>
  <condition>Substance Abuse</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive screening, testing, immunization, and risk reduction. Screening and testing will take place at study entry, immunization will occur at entry and after 3 and 6 months, and risk reduction will take place at study entry and after 3 and 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive enhanced treatment as usual.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Twinrix</intervention_name>
    <description>This vaccine will be given in three parts: at entry and after 3 and 6 months.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Enhanced treatment as usual</intervention_name>
    <description>Participants will receive comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, HAV and HBV immunizations, and any necessary treatments.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or
             major depression

          -  Diagnosis of a substance use disorder

          -  Enrolled in clinical care at Creative Alternatives or People Encouraging People for at
             least 3 months

        Exclusion Criteria:

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley D. Rosenberg, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisa Dixon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland, Department of Psychaitry</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rosenberg S, Brunette M, Oxman T, Marsh B, Dietrich A, Mueser K, Drake R, Torrey W, Vidaver R. The STIRR model of best practices for blood-borne diseases among clients with serious mental illness. Psychiatr Serv. 2004 Jun;55(6):660-4.</citation>
    <PMID>15175463</PMID>
  </reference>
  <reference>
    <citation>Rosenberg SD, Drake RE, Brunette MF, Wolford GL, Marsh BJ. Hepatitis C virus and HIV co-infection in people with severe mental illness and substance use disorders. AIDS. 2005 Oct;19 Suppl 3:S26-33.</citation>
    <PMID>16251824</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2006</study_first_submitted>
  <study_first_submitted_qc>April 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2006</study_first_posted>
  <results_first_submitted>April 4, 2013</results_first_submitted>
  <results_first_submitted_qc>April 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 22, 2013</results_first_posted>
  <last_update_submitted>April 4, 2013</last_update_submitted>
  <last_update_submitted_qc>April 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Serious Mental Illness</keyword>
  <keyword>Dual Diagnosis</keyword>
  <keyword>Mental Disorders</keyword>
  <keyword>Substance-Related Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with co-occuring mental illness and substance use disorders who were receiving services from 2 publicly funded community mental health programs in Baltimore, MD.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>STIRR Intervention</title>
          <description>The STIRR Intervention involves Screening for HIV and hepatitis C risk factors, Testing for HIV and hepatitis B and C infection, Immunization against hepatitis A and B, and Reducing risk and Referring for medical treatment for persons testing positive for HIV and hepatitis C.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Participants will receive enhanced treatment as usual. This entails comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, hepatitis A (HAV) and hepatitis B (HBV)immunizations, and any necessary treatments.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>STIRR Intervention</title>
          <description>The STIRR Intervention involves Screening for HIV and hepatitis C risk factors, Testing for HIV and hepatitis B and C infection, Immunization against hepatitis A and B, and Reducing risk and Referring for medical treatment for persons testing positive for HIV and hepatitis C.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Participants will receive enhanced treatment as usual. This entails comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, hepatitis A (HAV) and hepatitis B (HBV)immunizations, and any necessary treatments.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="118"/>
            <count group_id="B2" value="118"/>
            <count group_id="B3" value="236"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.6" spread="8.5"/>
                    <measurement group_id="B2" value="46.3" spread="9.3"/>
                    <measurement group_id="B3" value="46.5" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Immunization Status</title>
        <description>Of the participants that were not immunized at baseline, the number of participants who were immunized for Hepatitis A and B at 6 months.</description>
        <time_frame>Measured at 6 Months relative to Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>STIRR Intervention</title>
            <description>The STIRR Intervention involves Screening for HIV and hepatitis C risk factors, Testing for HIV and hepatitis B and C infection, Immunization against hepatitis A and B, and Reducing risk and Referring for medical treatment for persons testing positive for HIV and hepatitis C.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants will receive enhanced treatment as usual. This entails comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, hepatitis A (HAV) and hepatitis B (HBV)immunizations, and any necessary treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Immunization Status</title>
          <description>Of the participants that were not immunized at baseline, the number of participants who were immunized for Hepatitis A and B at 6 months.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wald Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tested for Hepatitis C</title>
        <description>Participant self-report of being tested for hepatitis C</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>STIRR Intervention</title>
            <description>The STIRR Intervention involved Screening for HIV and hepatitis C risk factors, Testing for HIV and hepatitis B and C infection, Immunization against hepatitis A and B, and Reducing risk and Referring for medical treatment for persons testing positive for HIV and hepatitis C.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants will receive enhanced treatment as usual. This entails comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, hepatitis A and hepatitis B immunizations, and any necessary treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Tested for Hepatitis C</title>
          <description>Participant self-report of being tested for hepatitis C</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wald Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tested for Hepatitis B</title>
        <description>Participant self-report of being tested for hepatitis B</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>STIRR Intervention</title>
            <description>The STIRR Intervention involved Screening for HIV and hepatitis C risk factors, Testing for HIV and hepatitis B and C infection, Immunization against hepatitis A and B, and Reducing risk and Referring for medical treatment for persons testing positive for HIV and hepatitis C.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants will receive enhanced treatment as usual. This entails comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, HAV and HBV immunizations, and any necessary treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Tested for Hepatitis B</title>
          <description>Participant self-report of being tested for hepatitis B</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wald Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tested for HIV</title>
        <description>Participant self-report of being tested for HIV</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>STIRR Intervention</title>
            <description>The STIRR Intervention involved Screening for HIV and hepatitis C risk factors, Testing for HIV and hepatitis B and C infection, Immunization against hepatitis A and B, and Reducing risk and Referring for medical treatment for persons testing positive for HIV and hepatitis C.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants will receive enhanced treatment as usual. This entails comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, HAV and HBV immunizations, and any necessary treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Tested for HIV</title>
          <description>Participant self-report of being tested for HIV</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Wald Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Referral for Medical Care</title>
        <description>For participants infected with hepatitis C, their self-report of being referred for medical care.</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>STIRR Intervention</title>
            <description>The STIRR Intervention involved Screening for HIV and hepatitis C risk factors, Testing for HIV and hepatitis B and C infection, Immunization against hepatitis A and B, and Reducing risk and Referring for medical treatment for persons testing positive for HIV and hepatitis C.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants will receive enhanced treatment as usual. This entails comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, HAV and HBV immunizations, and any necessary treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Referral for Medical Care</title>
          <description>For participants infected with hepatitis C, their self-report of being referred for medical care.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>STIRR Intervention</title>
          <description>The STIRR Intervention involved Screening for HIV and hepatitis C risk factors, Testing for HIV and hepatitis B and C infection, Immunization against hepatitis A and B, and Reducing risk and Referring for medical treatment for persons testing positive for HIV and hepatitis C.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Participants will receive enhanced treatment as usual. This entails comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, HAV and HBV immunizations, and any necessary treatments.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stanley Rosenberg, Ph.D.</name_or_title>
      <organization>Dartmouth-Hitchcock</organization>
      <phone>603-653-0740</phone>
      <email>Stanley.d.rosenberg@dartmouth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

